I am originally from India and hold a Bachelor’s degree in Life Sciences from Delhi University and a Master’s in Forensic Science from the National Forensic Science University. Currently, I am a joint PhD student at AcSIR and the University of Western Australia. I spent the initial three years of my research in India, where I gained extensive hands-on experience with various analytical instruments, including HPLC, LC-MS, GC-MS, UV-Vis spectrophotometry, FTIR, DLS and AFS. My research interests lie in material synthesis, and I am currently focused on nano-based drug delivery methods. My expertise bridges analytical techniques and nanotechnology applications, contributing to advancements in targeted therapeutic delivery systems.
My passion for research stems from a deep interest in nanomedicine and its potential to revolutionize drug delivery. I am always curious and fascinated by material synthesis and the development of nanoscale systems for targeted therapeutics. This led me to explore nano-drug delivery strategies that enhance drug stability, bioavailability, and precision in targeting diseased tissues.
I joined the Biomedical Analysis ARC Training Centre at UWA to advance my expertise in Nano delivery techniques and their applications in medicine. The Centre’s strong focus on translational research, cutting-edge nanotechnology, and interdisciplinary collaborations provides the ideal environment to develop innovative solutions for therapeutic delivery. By integrating nanomaterials with biomedical applications, I aim to contribute to the development of more efficient and targeted drug delivery systems, ultimately improving patient outcomes in healthcare.
My current research focuses on the development of lipid-based nanocarriers for targeted drug delivery to the kidneys, aiming to mitigate the toxic effects of endocrine-disrupting chemicals (EDCs). EDCs, commonly found in industrial pollutants, pharmaceuticals, and personal care products, pose significant health risks by interfering with hormonal regulation and causing renal toxicity. Conventional detoxification strategies often fail to provide organ-specific protection, necessitating advanced delivery systems for precise therapeutic intervention.
The primary objective of my research is to engineer lipid nanocarriers that can selectively accumulate in kidney tissues, enhancing the bioavailability of protective agents while minimizing systemic side effects. By optimizing the physicochemical properties of these nanocarriers, including size, surface charge, and ligand functionalization, my study aims to improve renal targeting efficiency. Advanced characterization techniques and in vitro/in vivo models will be employed to assess their efficacy in preventing EDC-induced nephrotoxicity.
This research has significant implications for both biomedical science and public health. The successful development of kidney-targeted nanocarriers could pave the way for novel therapeutic approaches to prevent or mitigate renal damage caused by environmental toxins, pharmaceutical residues, and metabolic disorders. Additionally, this work contributes to the broader field of nanomedicine by
advancing precision drug delivery strategies, potentially reducing the burden of kidney-related diseases. By integrating nanotechnology with toxicology and renal medicine, this research holds promise for improving patient outcomes and enhancing environmental health protection strategies.
Through my research, I aim to develop an efficient lipid-based nanocarrier system that can selectively target the kidneys and mitigate the toxic effects of endocrine-disrupting chemicals (EDCs). By optimizing nanocarrier design for enhanced renal accumulation and therapeutic efficacy, I hope to contribute to the advancement of precision drug delivery strategies in nanomedicine. Ultimately, my goal is to provide a novel, targeted approach to protect kidney function from environmental and pharmaceutical toxins, improving patient outcomes and public health.
The Biomedical Analysis ARC Training Centre at UWA provides the ideal platform to achieve these objectives. With its cutting-edge nanotechnology facilities, interdisciplinary collaborations, and strong focus on translational research, the Centre offers invaluable expertise and resources to refine and validate my lipid nanocarrier system. Additionally, access to industry partnerships and expert mentorship will enable me to translate my findings into impactful biomedical applications, furthering advancements in targeted renal therapy.
To sign off, one interesting fact about me is that I easily get bored with monotonous routines, so I’m always looking for new challenges or hobbies—whether experimenting with new recipes or trying adventure sports!
